AstraZeneca's Brilinta, or ticagrelor, was approved by the FDA for preventing blood clots in patients with acute coronary syndrome. In clinical tests, Brilinta proved "more effective than Plavix in preventing heart attacks and death, but that advantage was seen with aspirin maintenance doses of 75 to 100 milligrams once daily," the agency said. Brilinta will carry a boxed warning about bleeding risk and reduced effectiveness
if taken with more than 100 milligrams of aspirin. Sanofi and Bristol-Myers Squibb market Plavix.